Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F

NCT07227285 is registered in ClinicalTrials.gov with Cyllene Therapeutics as lead sponsor.

NCT NCT07227285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F
Lead sponsor
Cyllene Therapeutics
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
April 30, 2031
Enrollment
16 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

spinal cord injury, urinary bladder, overactive